valsartan (Q155472)

From Wikidata

Jump to navigation Jump to search

angiotensin II receptor antagonist (commonly called an ARB, or angiotensin receptor blocker), that is selective for the type I (AT1) angiotensin receptor

VAL489
CGP-48933
N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine
N-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
(S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine

Language	Label	Description	Also known as
English	valsartan	angiotensin II receptor antagonist (commonly called an ARB, or angiotensin receptor blocker), that is selective for the type I (AT1) angiotensin receptor	VAL489 CGP-48933 N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine N-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine (S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine

Statements

type of chemical entity

0 references

heterocyclic compound

0 references

carboxylic acid

0 references

0 references

chemical structure

Valsartan.svg
648 × 472; 4 KB

1 reference

imported from Wikimedia project

German Wikipedia

435.22704 dalton

1 reference

language of work or name

137862-53-4 (English)

4 October 2016

significant event

Valsartan recall: global regulatory overview and future challenges

2018

0 references

Diovan Incident

2013

0 references

stereoisomer of

1 reference

based on heuristic

inferred from InChI

N-(1-Oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]methyl]-L-valine

1 reference

based on heuristic

inferred from InChI

chemical formula

C₂₄H₂₉N₅O₃

1 reference

language of work or name

137862-53-4 (English)

19 November 2016

canonical SMILES

CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O

1 reference

language of work or name

137862-53-4 (English)

19 November 2016

isomeric SMILES

CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O

1 reference

language of work or name

137862-53-4 (English)

19 November 2016

defined daily dose

80 milligram

route of administration

oral administration

1 reference

https://www.whocc.no/atc_ddd_index/?code=C09CA03

active ingredient in

1 reference

14 February 2018

World Health Organisation international non-proprietary name

valsartan (English)

2 references

language of work or name

valsartan (English)

4 October 2016

Recommended INN: List 33

publication date

1993

medical condition treated

congestive heart failure

1 reference

language of work or name

13 December 2016

arterial hypertension

2 references

language of work or name

13 December 2016

Drug Indications Extracted from FAERS

2 October 2018

1 reference

Drug Indications Extracted from FAERS

2 October 2018

significant drug interaction

lisinopril dihydrate

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

lisinopril dihydrate

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(+-)-flurbiprofen

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

increased systemic arterial blood pressure

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

increased systemic arterial blood pressure

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

increased systemic arterial blood pressure

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

increased systemic arterial blood pressure

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

increased systemic arterial blood pressure

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

increased systemic arterial blood pressure

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

increased systemic arterial blood pressure

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(+-)-flurbiprofen

increased systemic arterial blood pressure

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(+-)-flurbiprofen

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

increased systemic arterial blood pressure

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

increased systemic arterial blood pressure

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

increased systemic arterial blood pressure

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

increased systemic arterial blood pressure

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

increased systemic arterial blood pressure

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

increased systemic arterial blood pressure

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

increased systemic arterial blood pressure

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

lisinopril dihydrate

acute kidney injury

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

lisinopril dihydrate

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

lisinopril dihydrate

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

acute kidney injury

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

acute kidney injury

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

acute kidney injury

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

acute kidney injury

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

acute kidney injury

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

acute kidney injury

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

acute kidney injury

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

increased blood creatinine

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

increased blood creatinine

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

increased blood creatinine

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

increased blood creatinine

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

angiotensin II receptor type 1

subject has role

2 references

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

Open Targets Platform

14 August 2023

https://platform.opentargets.org/drug/CHEMBL1069

legal status (medicine)

1 reference

https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802

FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links. (English)

pregnancy category

US pregnancy category D

1 reference

imported from Wikimedia project

English Wikipedia

LiverTox likelihood score

LiverTox toxicity likelihood category D

1 reference

8 April 2021

https://www.ncbi.nlm.nih.gov/books/n/livertox/Valsartan

13 January 2017

subject has role

angiotensin II receptor antagonist

1 reference

Medical Subject Headings

MeSH descriptor ID

15 March 2018

antihypertensive drug

1 reference

Medical Subject Headings

MeSH descriptor ID

15 March 2018

0 references

0 references

Commons category

Valsartan

0 references

Identifiers

InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1

1 reference

language of work or name

137862-53-4 (English)

19 November 2016

ACWBQPMHZXGDFX-QFIPXVFZSA-N

2 references

language of work or name

137862-53-4 (English)

19 November 2016

ChEBI release 2020-09-01

CAS Registry Number

2 references

Global Substance Registration System

language of work or name

valsartan (English)

19 November 2016

ACWBQPMHZXGDFX-QFIPXVFZSA-N

CAS Common Chemistry

9 April 2021

https://commonchemistry.cas.org/detail?cas_rn=137862-53-4

1 reference

language of work or name

Valsartan (English)

19 November 2016

2 references

language of work or name

137862-53-4 (English)

19 November 2016

matched by identifier from

ACWBQPMHZXGDFX-QFIPXVFZSA-N

Reaxys registry number

7754038

1 reference

language of work or name

valsartan (English)

4 October 2016

mapping relation type

2 references

language of work or name

VALSARTAN (English)

19 November 2016

matched by identifier from

International Chemical Identifier

InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1

1 reference

language of work or name

VALSARTAN (English)

19 November 2016

2 references

based on heuristic

inferred from InChIKey

matched by identifier from

ACWBQPMHZXGDFX-QFIPXVFZSA-N

2 references

based on heuristic

inferred from InChIKey

matched by identifier from

ACWBQPMHZXGDFX-QFIPXVFZSA-N

UniChem compound ID

1 reference

MassBank accession ID

0 references

0 references

MSBNK-Athens_Univ-AU111201

0 references

MSBNK-Athens_Univ-AU111202

0 references

MSBNK-Athens_Univ-AU111203

0 references

MSBNK-Athens_Univ-AU111204

0 references

MSBNK-Athens_Univ-AU111205

0 references

MSBNK-Athens_Univ-AU111206

0 references

MSBNK-Athens_Univ-AU111207

0 references

MSBNK-Athens_Univ-AU111208

0 references

MSBNK-Athens_Univ-AU111209

0 references

MSBNK-Athens_Univ-AU111210

0 references

MSBNK-Athens_Univ-AU111211

0 references

MSBNK-Athens_Univ-AU111251

0 references

MSBNK-Athens_Univ-AU111252

0 references

MSBNK-Athens_Univ-AU111253

0 references

MSBNK-Athens_Univ-AU111254

0 references

MSBNK-Eawag-EA258301

0 references

MSBNK-Eawag-EA258302

0 references

MSBNK-Eawag-EA258303

0 references

MSBNK-Eawag-EA258304

0 references

MSBNK-Eawag-EA258305

0 references

MSBNK-Eawag-EA258306

0 references

MSBNK-Eawag-EA258307

0 references

MSBNK-Eawag-EA258308

0 references

MSBNK-Eawag-EA258309

0 references

MSBNK-Eawag-EA258310

0 references

MSBNK-Eawag-EA258311

0 references

MSBNK-Eawag-EA258312

0 references

MSBNK-Eawag-EA258313

0 references

MSBNK-Eawag-EA258314

0 references

MSBNK-Eawag-EA258351

0 references

MSBNK-Eawag-EA258352

0 references

MSBNK-Eawag-EA258353

0 references

MSBNK-Eawag-EA258354

0 references

MSBNK-Eawag-EA258355

0 references

MSBNK-Eawag-EA258356

0 references

MSBNK-Eawag-EA258358

0 references

MSBNK-Eawag-EA258359

0 references

MSBNK-Eawag-EA258360

0 references

MSBNK-Eawag-EA258361

0 references

MSBNK-Eawag-EA258362

0 references

MSBNK-Eawag-EA258364

0 references

MSBNK-KWR-KW107501

0 references

MSBNK-KWR-KW107502

0 references

MSBNK-KWR-KW107503

0 references

MSBNK-KWR-KW107504

0 references

MSBNK-UPAO-UPA00017

0 references

MSBNK-Waters-WA002356

0 references

MSBNK-Waters-WA002357

0 references

MSBNK-Waters-WA002358

0 references

MSBNK-Waters-WA002359

0 references

MSBNK-Waters-WA002360

0 references

MSBNK-Waters-WA002361

0 references

splash10-0a4u-0190000000-8a48f701b19b54e7ebf9

0 references

splash10-0a4u-0190000000-34257438319cae238dcb

0 references

splash10-0a4i-0590000000-403ef14fce06289de8e7

0 references

splash10-0a59-0960000000-d4e79af5b474f613f6e9

0 references

splash10-052u-0093000000-ee050d1727838e542ce7

0 references

splash10-001i-0000900000-45397dbc5403f1111d85

0 references

splash10-003r-0303900000-1056988fef13dc9becc8

0 references

splash10-004i-0900000000-65d8dfbf9280fcea77fb

0 references

splash10-004i-0900000000-77a9588a3e936c9d2e28

0 references

splash10-066r-0013900000-27f31e9591de9c0d036b

0 references

splash10-0a4u-0096600000-2c9e5fef1cb7e2e64e67

0 references

splash10-0a4u-0091000000-0bff344a92ee0cc41b8f

0 references

splash10-0a4i-0390000000-fa2f74ef15c1a6b93838

0 references

splash10-0a59-0960000000-ca847cc390cd0e68c6b6

0 references

splash10-0pec-0920000000-5c29e64b37c8cde1c7ba

0 references

splash10-0ziu-0910000000-08f3eecf83a71f4fb485

0 references

splash10-0a4u-0096600000-598ea56da3433ecd4bab

0 references

splash10-0a4u-0091000000-0aaf7a6567cb3745cb23

0 references

splash10-0a4i-0490000000-4b8d8ce6d0a486599b71

0 references

splash10-0a59-0950000000-6cd1be141d3f05844a75

0 references

splash10-0pec-0920000000-053a50818908a33699b3

0 references

splash10-0ziu-0910000000-c10b0879c877503826c5

0 references

splash10-066r-0013900000-af025bf00303b40b6d48

0 references

splash10-0udi-0009000000-160f82ad0952fc9b3350

0 references

splash10-001i-0000900000-d7bf9d8976f47e44ab4a

0 references

splash10-0fb9-0915000000-1f5a4e134cd8450810e7

0 references

splash10-004i-0900000000-19095db3835430e9fe16

0 references

splash10-004i-0900000000-00e9b9924b37c4db7a8d

0 references

splash10-004i-0900000000-fb8741bb91ee87d8245e

0 references

splash10-001i-0000900000-be5ab1c8cde8851235e3

0 references

splash10-0fb9-0915000000-08501c181e1066f2aa0a

0 references

splash10-004i-0900000000-6cabcfa5948837eddb2e

0 references

splash10-004i-0900000000-d0aedd0bab06b374571a

0 references

splash10-004i-0901000000-a4572421f0a393f299a1

0 references

splash10-0udi-0009000000-0f743f9e78dce83f2414

0 references

splash10-0ufr-0519300000-01a7bb4eb9b2a03d04d7

0 references

splash10-0a4i-0122900000-e2d5ae1b4433254a8ebe

0 references

splash10-0a4u-1492000000-bc19c44b1bd382b3180f

0 references

splash10-0a4u-0391100000-8997765a9ed3c9424c07

0 references

splash10-003r-0912600000-feeef5a05d8ef569460d

0 references

1 reference

Hazardous Substances Data Bank

publication date

28 October 2019

VALSARTAN (English)

10 May 2021

DSSTox substance ID

1 reference

matched by identifier from

ACWBQPMHZXGDFX-QFIPXVFZSA-N

DSSTOX compound identifier

0 references

0 references

0 references

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

27 December 2018

(2S)-3-methyl-2-[N-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid (English)

CAS no.: 137862-53-4 (English)

ECHA Substance Infocard ID

1 reference

http://echa.europa.eu/de/information-on-chemicals/registered-substances

1 reference

language of work or name

Valsartan (English)

publication date

17 November 2015

World Health Organisation international non-proprietary name numeric ID

1 reference

https://mednet-communities.net/inn/db/ViewINN.aspx?i=7016

Guide to Pharmacology Ligand ID

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

valsartan (English)

19 November 2016

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

5 February 2021

MeSH descriptor ID

subject named as

Valsartan

1 reference

Medical Subject Headings

MeSH descriptor ID

14 March 2018

D03.383.129.617.850

0 references

D12.125.070.950.550

0 references

D12.125.142.930.500

0 references

1 reference

Global Substance Registration System

language of work or name

valsartan (English)

19 November 2016

1 reference

matched by identifier from

ACWBQPMHZXGDFX-QFIPXVFZSA-N

Human Metabolome Database ID

2 references

based on heuristic

inferred from InChIKey

matched by identifier from

ACWBQPMHZXGDFX-QFIPXVFZSA-N

2 references

Global Substance Registration System

language of work or name

valsartan (English)

19 November 2016

matched by identifier from

ACWBQPMHZXGDFX-QFIPXVFZSA-N

MedlinePlus drug identifier

0 references

PatientsLikeMe treatment ID

0 references

1 reference

Global Substance Registration System

language of work or name

valsartan (English)

19 November 2016

Probes And Drugs ID

0 references

1 reference

1 reference

language of work or name

valsartan (English)

4 October 2016

0 references

1 reference

Freebase Data Dumps

publication date

28 October 2013

Interlingual Index ID

0 references

Microsoft Academic ID

0 references

1 reference

26 January 2022

https://docs.openalex.org/download-snapshot/snapshot-data-format

Römpp online ID

1 reference

imported from Wikimedia project

German Wikipedia

UK Parliament thesaurus ID

subject named as

Valsartan

0 references

1 reference

Global Substance Registration System

language of work or name

valsartan (English)

19 November 2016

1 reference

based on heuristic

inferred by common MeSH mappings on source and on Wikidata

25 May 2023

WikiProjectMed ID

0 references

WordNet 3.1 Synset ID

04526314-n

1 reference

Sitelinks

Wikipedia(32 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(1 entry)

commonswiki Category:Valsartan

Retrieved from "https://www.wikidata.org/w/index.php?title=Q155472&oldid=2257417365"